glp 1 receptor agonists mechanism of action Frontiers Discovery of GLP-1–Based Drugs for

This results in a lower ability to promote receptor internalization compared with endogenous GLP-1, so it allows to have an increased GLP-1R expression on the cell surface, which translates in more robust insulinotropic properties, possibly explaining the enhanced insulin secretion (in both diabetic and not diabetic human islets), induced by TZP (48) ( Figure 1 )

For detailed comparison of these medication options, see our Zepbound vs Wegovy guide

likewise, compensatory hyperinsulinemia in the setting of insulin resistance could also contribute to anomalies in vaso-reactivity, angiogenesis, and fibrosis implicated in CKD and atherogenesis [53]

JNK, c-Jun N-terminal kinase